Compare McKesson Corporation (MCK) vs SOLAI Limited (SLAI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
McKesson Corporation vs SOLAI Limited — how do they compare? McKesson Corporation trades at $824.51 (market cap $97.35B), while SOLAI Limited trades at $3.72 (market cap $16.69M). The key difference: McKesson Corporation is far larger — about 5832.8× SOLAI Limited's market cap, and McKesson Corporation pays a 0.39% dividend while SOLAI Limited pays none. Which is the better fit depends on your goals.
| MCK | SLAI | |
|---|---|---|
Market Cap | $97.35B | $16.69M |
Sector | Health | Technology |
52-Week High | $995.69 | $26.74 |
52-Week Low | $659.01 | $2.74 |
Enterprise Value | $101.98B | $16.33M |
Dividend Yield | 0.39% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
McKesson Corporation (MCK) trades at $831.60, down 1.16% on the day, with a bullish technical signal and positive earnings momentum after beating estimates for three consecutive quarters. The stock shows strong analyst support with an 80% buy rating and a consensus price target of $932.83, implying potential upside. Revenue growth is robust, reaching $359.05 billion in 2025, though net margins remain thin at 1.18%. Cash flow from operations improved to $6.09 billion in 2025, supporting financial stability.
The outlook for MCK is positive, driven by earnings beats, analyst optimism, and solid cash generation. Key opportunities include growth in specialty pharma and oncology services. Risks involve policy uncertainties, competitive pressures, and execution challenges. The stock's current price near key support at $829 suggests a critical level for near-term direction.
SLAI trades at $3.72 with no recent price movement, while facing NYSE delisting proceedings announced July 16, 2026. The company shows severe financial distress with negative gross profit margin of -44.87% and net income margin of -134.63% for 2025. Recent developments include a 7:1 reverse stock split effective June 2026 and acquisition of a 51% stake in NEURALAND. Technical indicators show mixed signals with an overall bullish trend but overbought RSI conditions.
The outlook remains highly speculative given delisting risks and persistent losses. Investment opportunity exists only for speculative traders betting on turnaround potential from recent acquisitions and AI product launches. Primary risks include imminent delisting, negative cash flow, and unsustainable financial performance that threatens ongoing operations.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About McKesson Corporation
McKesson is a leading wholesaler of branded, generic, and specialty pharmaceutical products to pharmacies (retail chains, independent, and mail order), hospitals networks, and healthcare providers. Along with AmerisourceBergen and Cardinal Health, the three account for well over 90% of the U.S. pharmaceutical wholesale industry. McKesson is currently divesting from its pharmaceutical wholesale and distribution in Europe and Canada in order to redeploy capital to strategic growth areas in the U.S. (oncology network and ecosystem, and biopharma services). Additionally, the company supplies medical-surgical products and equipment to healthcare facilities and provides a variety of technology solutions for pharmacies.
Read more on MCK →About SOLAI Limited
SOLAI focuses on providing innovative AI-driven software solutions. The company leverages artificial intelligence to enhance digital experiences and optimize business processes for various industries.
Read more on SLAI →
